Kyowa’s buyout of Orchard adds to a half dozen other gene therapy acquisitions over the past year. While the dealmaking is in some respects an encouraging sign, the sale prices have been modest and typically followed business setbacks for the acquired companies.
Broadly, gene therapy developers have struggled with ebbing investor enthusiasm for their typically costly research as well as evidence in Europe and the U.S. that marketing the one-time treatments can be a slow and difficult process.
